華領醫藥:2024年銷售收入2.559億元,同比增234%,華堂寧®銷量暴增740%
華領醫藥(2552.HK)公佈業績,2024年是公司核心產品華堂寧®進入國家醫保藥品目錄後的首個完整銷售年度。公司銷售收入達2.559億元,較2023年增加234%;共銷售約210.5萬盒華堂寧®,較2023年增加約740%。華堂寧®的銷售覆蓋約2700家醫院。2025年,華領醫藥建立了藥品市場銷售團隊,華堂寧®在年初展現出了良好的增長勢頭,前兩月共售出約59.2萬盒華堂寧®,淨銷售額約7320萬元;相比2024年同期的20.2萬盒和2450萬元,淨銷售淨額增長顯著,在每盒價格維持不變的情況下,銷售額增長199%。截至2024年12月31日,華領醫藥現金結餘達11.398億元,以支持公司的全面商業化、業務發展和研發活動。2024年,華領醫藥成功完成並公佈了第二代GKA(HM-002-1005)在美國的單劑量遞增(SAD)研究結果,驗證了每日一次口服療法用於肥胖2型糖尿病患者的可行性。公司目前正在開發臨牀劑型,以推進HM-002-1005的臨牀機制驗證研究。據悉,華領醫藥正在準備多格列艾汀在中國澳門和中國香港市場的商業化的註冊申請材料,公司計劃在2025年提交這兩項申請。今年二月發表的一個孟德爾隨機化研究提示, GKA可能通過抗炎和延緩生物衰老機制改善糖尿病患者的虛弱和肌肉減少症。此外,腎功能不全患者無需調整劑量的優勢,爲合併肥胖及代謝綜合徵的糖尿病患者提供了長期用藥的可行性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.